180 Wealth Advisors LLC Lowers Position in Illumina, Inc. (NASDAQ:ILMN)

180 Wealth Advisors LLC lowered its stake in Illumina, Inc. (NASDAQ:ILMN) by 2.6% during the 4th quarter, Holdings Channel reports. The firm owned 20,168 shares of the life sciences company’s stock after selling 538 shares during the quarter. 180 Wealth Advisors LLC’s holdings in Illumina were worth $2,695,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Zacks Investment Management purchased a new position in shares of Illumina during the 3rd quarter worth about $2,924,000. Freemont Management S.A. purchased a new position in shares of Illumina during the third quarter valued at approximately $1,565,000. Weybosset Research & Management LLC boosted its position in shares of Illumina by 92.0% during the third quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company’s stock valued at $2,354,000 after buying an additional 8,650 shares during the period. B. Riley Wealth Advisors Inc. grew its stake in shares of Illumina by 176.3% during the second quarter. B. Riley Wealth Advisors Inc. now owns 7,176 shares of the life sciences company’s stock valued at $749,000 after buying an additional 4,579 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Illumina by 65.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 32,806 shares of the life sciences company’s stock worth $4,278,000 after buying an additional 12,986 shares during the period. Institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on ILMN shares. Robert W. Baird lifted their target price on Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Piper Sandler lowered their price objective on shares of Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a research report on Thursday, October 17th. Hsbc Global Res upgraded Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective on the stock in a report on Thursday, October 17th. Finally, Royal Bank of Canada increased their price target on Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Eight analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and a consensus price target of $165.63.

Illumina Trading Up 5.5 %

Illumina stock opened at $144.22 on Tuesday. Illumina, Inc. has a 52 week low of $100.08 and a 52 week high of $156.66. The stock has a 50-day moving average price of $140.92 and a 200 day moving average price of $132.88. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The company has a market capitalization of $22.87 billion, a price-to-earnings ratio of -14.48 and a beta of 1.11.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. During the same period in the previous year, the business posted $0.33 EPS. The business’s quarterly revenue was down 3.5% compared to the same quarter last year. Sell-side analysts anticipate that Illumina, Inc. will post 4.11 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.